SCHEMBL376898

SCHEMBL376898

N#Cc1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 3/20 0.60
KDM4E B2RXH2 2/20 0.59
ALDH1A1 P00352 1/20 0.59
GAA P10253 1/20 0.59
MAPT P10636 1/20 0.59
BCL2 P10415 6/20 0.58
BAK1 Q16611 4/20 0.58
KMT2A Q03164 1/20 0.56
LMNA P02545 1/20 0.56
ADORA1 P30542 1/20 0.56
DRD4 P21917 6/20 0.55
DRD2 P14416 5/20 0.55
DRD3 P35462 5/20 0.55
BCL2L1 Q07817 3/20 0.53
ADRA1D P25100 2/20 0.50
ADRA1A P35348 2/20 0.50
ADRA1B P35368 2/20 0.50
HTR1A P08908 2/20 0.50
DRD1 P21728 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1540287 0.88 BCL2 (0.60) HTR7KDM4EALDH1A1GAAMAPT
SCHEMBL15938164 0.86 HTR7 (0.81) HTR7KDM4EALDH1A1GAAMAPT
SCHEMBL19145578 0.84 HTR7 (0.81) HTR7KDM4EALDH1A1GAAMAPT
SCHEMBL1677378 0.82 HTR7 (0.50) HTR7KDM4EALDH1A1GAAMAPT
SCHEMBL1955274 0.81 BCL2 (0.58) BCL2BCL2L1
SCHEMBL20429252 0.81 BCL2 (0.63) HTR7KDM4EALDH1A1GAAMAPT
SCHEMBL1540289 0.81 BCL2 (0.60) HTR7KDM4EALDH1A1GAAMAPT
SCHEMBL1741405 0.80 BCL2 (0.71) HTR7KDM4EALDH1A1GAAMAPT
SCHEMBL29846744 0.80 BCL2 (0.71) HTR7KDM4EALDH1A1GAAMAPT
SCHEMBL12806160 0.80 BCL2 (0.50) HTR7KDM4EALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765778-B1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-01-25 EP disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-7585858-B2 N-sulfonylcarboximidamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-09-08 US disclosed
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters ABBVIE INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BAD HTR7 1936/4885KDM4E 1408/4885ALDH1A1 2354/4885
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters BAX, BCL2, BAD HTR7 1936/4885KDM4E 1408/4885ALDH1A1 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.